Ginkgo biloba affords dose‐dependent protection against 6‐hydroxydopamine‐induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences
- 17 February 2005
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 93 (1) , 94-104
- https://doi.org/10.1111/j.1471-4159.2005.03000.x
Abstract
Ginkgo biloba extract (EGb), a potent antioxidant and monoamine oxidase B (MAO-B) inhibitor, was evaluated for its anti-parkinsonian effects in a 6-hydroxydopamine (6-OHDA) rat model of the disease. Rats were treated with 50, 100, and 150 mg/kg EGb for 3 weeks. On day 21, 2 microL 6-OHDA (10 microg in 0.1% ascorbic acid saline) was injected into the right striatum, while the sham-operated group received 2 microL of vehicle. Three weeks after 6-OHDA injection, rats were tested for rotational behaviour, locomotor activity, and muscular coordination. After 6 weeks, they were killed to estimate the generation of thiobarbituric acid reactive substances (TBARS) and reduced glutathione (GSH) content, to measure activities of glutathione-S-transferase (GST), glutathione reductase (GR), glutathione peroxidase (GPx), catalase, and superoxide dismutase (SOD), and to quantify catecholamines, dopamine (DA) D2 receptor binding, and tyrosine hydroxylase-immunoreactive (TH-IR) fibre density. The increase in drug-induced rotations and deficits in locomotor activity and muscular coordination due to 6-OHDA injections were significantly and dose-dependently restored by EGb. The lesion was followed by an increased generation of TBARS and significant depletion of GSH content in substantia nigra, which was gradually restored with EGb treatment. EGb also dose-dependently restored the activities of glutathione-dependent enzymes, catalase, and SOD in striatum, which had reduced significantly by lesioning. A significant decrease in the level of DA and its metabolites and an increase in the number of dopaminergic D2 receptors in striatum were observed after 6-OHDA injection, both of which were significantly recovered following EGb treatment. Finally, all of these results were exhibited by an increase in the density of TH-IR fibers in the ipsilateral substantia nigra of the lesioned group following treatment with EGb; the lesioning had induced almost a complete loss of TH-IR fibers. Considering our behavioural studies, biochemical analysis, and immunohistochemical observation, we conclude that EGb can be used as a therapeutic approach to check the neuronal loss following parkinsonism.Keywords
This publication has 37 references indexed in Scilit:
- Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTPCell and tissue research, 2004
- Neuroprotective Effects of Bilobalide, a Component of Ginkgo biloba Extract (EGb 761®) in Global Brain Ischemia and in Excitotoxicity-induced Neuronal DeathPharmacopsychiatry, 2003
- Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence11Published on the World Wide Web 3 January 2001.Brain Research, 2001
- Extracts of ginkgo biloba leaves inhibit monoamine oxidasePublished by Elsevier ,1999
- A Magnetic Resonance Imaging Study of White Matter Lesions in Depression and Alzheimer's DiseaseThe British Journal of Psychiatry, 1996
- Free radicals, antioxidant enzymes, and carcinogenesisFree Radical Biology & Medicine, 1990
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- Methamphetamine-induced neuronal damage: A possible role for free radicalsNeuropharmacology, 1989
- Bromobenzene-Induced Liver Necrosis. Protective Role of Glutathione and Evidence for 3,4-Bromobenzene Oxide as the Hepatotoxic MetabolitePharmacology, 1974